FDA Commissioner Rob Califf (Photo by Michael Brochstein/Sipa USA)(Sipa via AP Images)

February 28, 2024 02:03 PM ESTUpdated 02:54 PM

Califf lays out drug shortage landscape, talks post-market data collection for accelerated approvals

Lia DeGroot

Efforts to inspect generic drug facilities around the world could end up worsening US shortages of several key medicines if they lead to halted manufacturing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Califf lays out drug shortage landscape, talks post-market data collection for accelerated approvals

Lia DeGroot

Sign up to read this article for free.

CagriSema’s weight loss data disappointed. What does Novo do next?

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

CMS explains what went into its first round of drug price negotiations

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

Bristol Myers' TYK2 inhibitor succeeds in pair of Phase 3 psoriatic arthritis trials

Califf lays out drug short­age land­scape, talks post-mar­ket da­ta col­lec­tion for ac­cel­er­at­ed ap­provals

Lia DeGroot

Sign up to read this article for free.

more like this

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

Califf lays out drug shortage landscape, talks post-market data collection for accelerated approvals

CagriSema’s weight loss data disappointed. What does Novo do next?

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

CMS explains what went into its first round of drug price negotiations

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

Bristol Myers' TYK2 inhibitor succeeds in pair of Phase 3 psoriatic arthritis trials